12tldr is a free AI article summarizer. Paste any article URL and get a structured summary with TL;DR bullet points, context, key details, and why it matters — all in seconds.

How does 12tldr work?

Paste an article URL into the input field and click Summarize. Our AI reads the article and generates a clear, structured summary. No signup or account is required.

Is 12tldr free to use?

Yes, 12tldr is completely free. No account, no subscription, no tracking required.

Which websites does 12tldr support?

12tldr works with articles from most major publications including The Economist, New York Times, Bloomberg, BBC, Reuters, The Guardian, Wired, and thousands of other websites.

What does the AI summary include?

Each summary includes a TL;DR with three bullet points, a 'What it's about' section, 'The details' with key facts, and 'Why it matters' — giving you a complete picture without reading the full article.

Enteral Beats IV Phosphate on Cost and Waste in ICU Trial

Source: journals.lww.com

TL;DR

Researchers ran a randomized trial in ICU patients with mild to moderate hypophosphatemia to test if enteral phosphate works as well as IV phosphate.
Enteral raised serum phosphate to 0.89 mmol/L at 24 hours, noninferior to IV's 0.82 mmol/L (difference 0.07 mmol/L, 95% CI –0.02 to 0.17 within 0.2 mmol/L margin).
Enteral cut costs 10-fold to $3.7 per patient, slashed waste by 209 g, and dropped CO₂ emissions 60-fold versus IV.

The story at a glance

This trial compared enteral versus IV phosphate replacement in 131 ICU patients at Royal Melbourne Hospital with serum phosphate levels of 0.3-0.75 mmol/L. Lead authors Chinh D. Nguyen and Adam M. Deane from University of Melbourne ran the study from April to July 2022 using an electronic medical record system for randomization. It shows enteral replacement matches IV on phosphate correction but adds big gains in cost and waste. Hypophosphatemia is common in critical illness and often treated with IV phosphate despite its fluid load and packaging.

Key points

Design: Prospective, single-center, parallel-group noninferiority trial in a 42-bed trauma, medical, and surgical ICU; modified intention-to-treat analysis of 131 patients.
Patients: Critically ill adults with serum phosphate 0.3-0.75 mmol/L (mild-moderate hypophosphatemia); baseline levels similar between groups.[[1]](https://journals.lww.com/ccmjournal/fulltext/2024/07000/a_randomized_noninferiority_trial_to_compare.7.aspx)[[2]](https://journals.lww.com/ccmjournal/abstract/2024/07000/a_randomized_noninferiority_trial_to_compare.7.aspx)
Interventions: Enteral phosphate (e.g., effervescent tablets) or IV phosphate (delivering ~20 mmol in ~408 mL solvent fluid, SD 372 mL).
Primary outcome: Serum phosphate at 24 hours; enteral 0.89 mmol/L (SD 0.24) vs. IV 0.82 mmol/L (SD 0.28); difference 0.07 mmol/L (95% CI, –0.02 to 0.17), meeting noninferiority margin of 0.2 mmol/L.[[3]](https://pubmed.ncbi.nlm.nih.gov/38537225)
Cost: Enteral $3.7 (SD $4.0) vs. IV $37.7 (SD $31.4) per patient; savings $34 (95% CI, $26.3-$41.7).
Waste: Enteral 7.7 g (SD 8.3 g) vs. IV 217 g (SD 169 g); reduction 209 g (95% CI, 168-250 g).
Environment: Enteral ~2 g phosphate produced 14.2 g CO₂; equivalent IV produced 843 g CO₂ equivalents (~60-fold more).

Details and context

Hypophosphatemia affects many ICU patients due to shifts from refeeding, respiratory alkalosis, or drugs like insulin. IV replacement is standard but adds fluid volume (risking overload in fluid-restricted patients) and generates plastic waste from bags/syringes.

The trial used electronic prompts for seamless delivery, limiting it to one center over ~2.5 months. No safety issues like hyperphosphatemia or GI intolerance were highlighted. Enteral avoids ~400 mL extra IV fluid per dose, which matters in sepsis or heart failure cases.

Secondary measures confirm practical benefits without biochemical harm; CO₂ estimates use life-cycle analysis for production/disposal.

Key quotes

"Enteral phosphate replacement in ICU is noninferior to IV replacement at a margin of 0.2 mmol/L but leads to a substantial reduction in cost and waste."[[1]](https://journals.lww.com/ccmjournal/fulltext/2024/07000/a_randomized_noninferiority_trial_to_compare.7.aspx)

Why it matters

Hypophosphatemia treatment shapes ICU resource use, fluid balance, and sustainability amid rising care demands. Clinicians can switch to enteral for mild-moderate cases, saving ~$34 per patient, cutting waste by over 200 g, and slashing emissions without losing efficacy. Watch for larger trials on severe hypophosphatemia or long-term outcomes, plus adoption in guidelines.